Ancha Baranova George Mason University, Fairfax, VA

Slides:



Advertisements
Similar presentations
CPL The Convergence of Bioinformatics and Medical Informatics -- PL Chang, M.D.
Advertisements

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Yan Guo Assistant Professor Department of Cancer Biology Vanderbilt University USA.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
16 November 2004Biomedical Imaging BMEN Biomedical Imaging of the Future Alvin T. Yeh Department of Biomedical Engineering Texas A&M University.
Cancer Cancer originates in dividing cells –Intestinal lining (colon) –Lung tissue –Breast tissue (glands/ducts) –Prostate (gland) –White blood cells.
The origin of metastatic disease: clues from genomics 7/13/2011.
Introduction to Genomics, Bioinformatics & Proteomics Brian Rybarczyk, PhD PMABS Department of Biology University of North Carolina Chapel Hill.
Tumor Markers Lecture one By Dr. Waheed Al-Harizi.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
---- Mark Borodovsky a short intro Position open: Scientist - Pathway Informatics (June 2009) THE POSITION The successful candidate will join the Computational.
Comprehensive Gene Expression Analysis of Prostate Cancer Reveals Distinct Transcriptional Programs Associated With Metastatic Disease Kevin Paiz-Ramirez.
Luděk Bláha, PřF MU, RECETOX BIOMARKERS AND TOXICITY MECHANISMS 13 – BIOMARKERS Summary and final notes.
Eleni Galani Medical Oncologist
Cancer What is cancer? How does it form? How can it be treated?
Cancer : A Genetic Disease Drill: 1.Write down 1 thing you know about the disease. 2.What would you most like to learn about cancer / What question would.
MH: 42 – 44 N: Cancer: Cell Division Gone Wrong.
The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Gene Hunting Natália F. Martins. Resumo Motivação Estratégia Automatização (?) Exemplos Referências.
Dr. Ziad W Jaradat Cancer Stem Cells. Recently biologically distinct and relatively rare populations of tumor-initiating cells have been identified in.
Tumor markers Present; by Dr. Andalib Isfahan Medical School
A New Oklahoma Bioinformatics Company. Microarray and Bioinformatics.
FINDING THE DISEASE GENES PROGRESS AND PROBLEMS THE HUMAN GENOME MAPPING PROJECT SEEKS TO READ THE FULL SEQUENCE OF THE HUMAN GENOME 3 Billion bases.
Introduction to Proteomics 1. What is Proteomics? Proteomics - A newly emerging field of life science research that uses High Throughput (HT) technologies.
Introduction of Department of Molecular Biology for Public Health in SCDC Ye Lu Shanghai Municipal Center for Disease Control & Prevention Shanghai Institute.
Tumor Markers.
Literature reviews revised is due4/11 (Friday) turn in together: revised paper (with bibliography) and peer review and 1st draft.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
分 子 病 理 實 驗 室 Molecular Pathology Lab 實驗室主持人:戚謹文, 周德盈 共同主持人 : 李芬瑤.
Construction of cancer pathways for personalized medicine | Presented By Date Construction of cancer pathways for personalized medicine Predictive, Preventive.
Apostolos Zaravinos and Constantinos C Deltas Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, Department of Biological.
Gene Expression Control of Gene Expression Activation of a gene that results in the formation of a _________. When transcription occurs a gene is “__________”
Ranjit Ganta, Raj Acharya, Shruthi Prabhakara Department of Computer Science and Engineering, Penn State University DATA WAREHOUSE FOR BIO-GEO HEALTH CARE.
Gene expression analysis of “complex” tissues What is gene expression? What is a “complex” tissue? How can gene expression analysis be done? How should.
Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:
OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best.
Decoding the Network Footprint of Diseases With increasing availability of data, there is significant activity directed towards correlating genomic, proteomic,
Cancer Basics EQ: What does cancer have to do with the cell cycle?
Lecture 11. Topics in Omic Studies (Cancer Genomics, Transcriptomics and Epignomics) The Chinese University of Hong Kong CSCI5050 Bioinformatics and Computational.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
Keratoconus genetics research at CERA Tuesday 24 November 2015 Professor Paul Baird Ocular Genetics Unit TRANSLATIONAL GENOMICS.
Cancer – a substance that causes cancer – a substance that causes cancer –Examples include tobacco smoke, ultraviolet rays, and asbestos Carcinogen.
Consumer Advocate Perspective Clinical Trials Registration Sharon F. Terry, JAM Sharon F. Terry, JAM President and CEO, Genetic Alliance, Inc. Founding.
Cancer Objective What is Cancer? Cancer is uncontrolled cell growth. (Mitosis) When you are young, your cells grow fast so because you are growing.
Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
(1) Genotype-Tissue Expression (GTEx) Largest systematic study of genetic regulation in multiple tissues to date 53 tissues, 500+ donors, 9K samples, 180M.
NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.
Cancer: Cell division gone wrong. A Basic Definition Cancer is : Disease caused by uncontrolled growth and division of defective cells. Disease caused.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
Evolution-informed Modeling discover biomarkers for precision oncology Li Liu, M.D. August 22, 2016.
Moiz Bakhiet, MD, PhD, Professor and Chairman
Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.
OMICS Journals are welcoming Submissions
Cyclins, Mutagens and Oncogenes
Yale SPORE in Skin Cancer
Gene expression.
Impact of Formal Methods in Biology and Medicine
Impact of Formal Methods in Biology and Medicine
Transcriptional Signature of Histone Deacetylases in Breast cancer
Coverage and Reimbursement to Genetic Testing
Tracing the Innate Genetic Evolution and Spatial Heterogeneity in Treatment Naïve Lung Cancer Lesions Jihye Kim Translational Bioinformatics and Cancer.
12th – 13th November GRANADA
Loyola Marymount University
One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.
Presentation transcript:

Ancha Baranova George Mason University, Fairfax, VA Genome, transcriptome and proteome features of malignant cells as a source of combinatorial biomarkers for clinical translation Ancha Baranova George Mason University, Fairfax, VA

Key word to understanding of cancer phenomenon PROGRESSION From bad to worse then to full catastrophe

LUNG CARCINOMA PROGRESSION e.g. carcinogen from the smoke e.g. Smoke

How long it usually takes: DECADES It takes ≈17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize Sequencing studies show that virtually all of the mutations necessary for metastasis are already present in all of the cells of the antecedent carcinoma. 10.1073/pnas.0712345105; Jones et al., 2008 17 years

TRUTH: Majority of human tumors sit in our bodies undiagnosed for decades Major implication for translational research: 1) need for early biomarkers; 2) need for evaluation of how far away the tumor was from sprouting metastasis  basis for post-surgical treatment and care

Problem: in biomarker research all low-hanging fruits already collected PSA, CEA, AFP….

Single biomarkers have problems with differentiating “grey area” diseases, i.e. inflammatory conditions Solution: Biomarker panels PSA LeveL Controls Prostate cancer Other cancers Benign genitourinary diseases BPH Barak et al., 1989

Now: from where these biomarker for biomarker panels are usually coming ? A fishing expedition: Differences often reflect Inflammation, fibrosis and other common properties Image courtesy of Purdue University, Dr. W. Andy Tao

Two-pronged approach proposed: TUMOR vs. a MIX of various normal cells Perform transcriptome (in silico) and proteome (using antigen screening) subtractions DISTANCE ANALYSIS: Use entire pattern of gene expression to evaluate of how far away the excised tumor was from sprouting metastasis Most TARGETED approach: Most GENERAL approach:

Two-pronged approach proposed: Based on previous works of collaborative consortium: TUMOR vs. a MIX of various normal cells Perform transcriptome (in silico) and proteome (using antigen screening) subtractions Most TARGETED approach: Will uncover tumor biomarkers that cannot be masked by antigen production in normal tissue

Most Targeted Approach: Consortium Blokhin Russian Oncological Scientific Center, Moscow (sample collection and processing) Caerus Discovery LLC, Manassas, VA (capture of protein biomarker as differentially expressed antigens) Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk (development of tumor protein biomarkers as targets for antibody-guided drug delivery) Biomedical Center, StPeterburg (differential display of tumor RNAs) Research Center for Medical Genetics RAMS (non-coding Tumor RNAs) George Mason University, Fairfax, USA (biomarker validation, bioinformatics support and general coordination) Most TARGETED approach:

Two-pronged approach proposed: DISTANCE ANALYSIS: Use entire pattern of gene expression to evaluate of how far away the excised tumor was from sprouting metastasis Most GENERAL approach:

Simple words explanation forusing entire transcriptome as biomarker Who is that? -- Instant answer (same person, Darwin) Biomarker approach: X: Distance from the end of nose to the upper lip Y: Diameter of the eye orbit Z: Number of hairs in the beard

Two-pronged approach proposed: Blokhin Russian Oncological Scientific Center, Moscow (sample collection and processing) Institute of Chemical Biology and Fundamental Medicine SB RAS, Novosibirsk (next gene sequencing and microarray) Vavilov Institute of General Genetics Research Center for Medical Genetics RAMS (distance analysis of samples based on summed evaluation of non-coding RNAs) University of Arkansas for Medical Sciences (Little Rock, AK) (distance analysis of whole genome patterns) George Mason University, Fairfax, USA (development of attractor descriptors, bioinformatics support and general coordination) DISTANCE ANALYSIS: Use entire pattern of gene expression to evaluate of how far away the excised tumor was from sprouting metastasis Most GENERAL approach:

VISION for the FUTURE New generation of tumor markers specific to the malignancy but not to the any normal cell type will allow: True early diagnostics of dormant tumors 2) More specific antibody-guided delivery of therapeutic agents to the tumors

VISION for the FUTURE Comparison of prognoses for This tumor and That tumor

Same strategy can be realized using NextGen Seq Very possible; low sequence coverage of transcripts will be enough; cost-efficient cut-off needs to be determined

VISION for the FUTURE REFERENCE LAB Profiles 100s normal samples for prostate; Establishes its own, equipment-specific NORMAL SPACE For every single tumor sample, the distance from normal tissue space is measured

How bad is my tumor? Answer: exact distance from “Ideal” norm Your tumor